Antibodies against Nε-homocysteinylated proteins in patients on different methods of renal replacement therapy

Kolarz, Marek; Małyszko, Jolanta; Stompór, Tomasz; Całka, Alicja; Undas, Anetta; Myśliwiec, M

doi:10.1515/cclm-2012-0527

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the recently recognized "non-traditional" risk factors of anincreased development of cardiovascular diseases in severe CKD stagesis is hyperhomocysteinemia (HHC) (Chuang et al, 2013;Qin et al, 2013;Baszczuk et al, 2014;Levi et al, 2014). Although many investigations have been devoted to the problem of HHC in CKD (Kolarz et al, 2012;Kolarz et al, 2013;Neigwekar et al, 2015;Zhang et al, 2015;Hang et al, 2016;Toda and Okamura, 2016;Heilman et al, 2017), a number of questions remain insufficiently clarified. Frequency of HHC depending on CKD stageis still unknown.…”

Section: Introductionmentioning

confidence: 99%

Hyperhomocysteinemia in patients with chronic kidney disease and its relationship with the functional status of the cardiovascular system

Postovitenko

Iliuk

Шевчук

et al. 2017

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is an important medical, social and economic problem nowadays. Patients with CKD are known to have an increased risk of development and progression of cardiovascular diseases. However, the causes and pathogenesis of cardiovascular complications are not well understood. One of the recently recognized “non-traditional” risk factors for the increased development of cardiovascular pathology in severe stages of CKD is hyperhomocysteinemia (HHC). The article presents the results of study of HHC frequency in patients with different stages of CKD as well as the relationship between HHC and endothelial dysfunction and structural-functional status of the heart. The study involved 148 persons with different stages of CKD who underwent immunoenzyme determination of total plasma homocysteine (HC), echocardiography, carotid ultrasonograghy, endothelial function was assessed as well. It was found that among the patients with CKD, 26 (21.1%) had normal and 34 (27.7%) had subnormal HC levels, mild HHC was observed in 30 (24.4%) and moderate HHC – in 33 (26.8%) cases, i.e. the total number of patients with elevated HC level was 88.9%. It should be noted that no patients with normal HC level were found among those with stage four CKD as well as in dialysis patients. The increase of blood plasma HC level was actually proportional to the severity of renal failure, which in its turn led to the shift in the number of cases towards higher rank indices of HHC level. In particular, while there were no patients with HHC among those with CKD-I, more than 50% of such patients were found in the group with CKD-V. Reduced myocardial contractility and echocardiographic markers of left ventricular hypertrophy in patients with CKD were found to be closely associated with HC concentrations in blood plasma. The data presented clearly demonstrate strong inverse correlation between endothelial dysfunction indices and HC level. So, the endothelium-dependent brachial artery vasodilation in patients with CKD-IV was lower by 3.8 and 1.5 times compared with control group and CKD-III group, respectively, and endothelium-independent vasodilation of the brachial artery – by 2.4 and 1.9 times, respectively. Correlation analysis also confirmed that impaired endothelium-dependent and endothelium-independent dilation with high statistical significance inversely correlated with the level of HC in blood plasma. Thus, the population of patients with CKD is characterized by high HHC frequency, which is closely associated with cardiovascular disorders (endothelial dysfunction, structural and functional remodelling of the myocardium) and can be an important risk factor for the development of vascular lesions. We believe that adequate correction of HHC, including administration of folic acid preparations could reduce the progression of vascular lesions in patients with CKD.

show abstract

Section: Introductionmentioning

confidence: 99%

Hyperhomocysteinemia in patients with chronic kidney disease and its relationship with the functional status of the cardiovascular system

Postovitenko

Iliuk

Шевчук

et al. 2017

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

show abstract

“…An additional effect of hyperhomocysteinaemia associated with cardiovascular risk and modulated by FA is post-translational protein Ne-homocysteinylation, which may trigger autoimmune response and lead to the formation of potentially harmful specific antibodies, as shown in patients with early-onset coronary artery disease or renal insufficiency [3,4]. Antibodies to Ne-homocysteinylated proteins may bind to them, with immune complex formation within the glomeruli and tubules; it is possible that lowering tHcy with FA may limit renal injury through mitigation of antibody formation.…”

mentioning

confidence: 99%

Folic acid improves renal function — in what mechanism?

Stompór

Undas

2015

Kardiol Pol

Self Cite

View full text Add to dashboard Cite

Paraoxonase 1 Activity and Renal Replacement Therapy for Chronic Renal Failure: A Meta-Analysis

Watanabe

Kotani

Iwazu

et al. 2023

JCM

View full text Add to dashboard Cite

Chronic renal failure (CRF) is associated with the development of cardiovascular disease (CVD). Paraoxonase 1 (PON1), an antioxidant enzyme, shows cardioprotective properties and has been proposed as a therapeutic marker for CRF. A systematic analysis of the literature assessing the association between PON1 activity and renal replacement therapy (RRT) of CRF is currently lacking. Therefore, we set out to perform a meta-analysis of the available data on PON1 in RRT of CRF. We searched three electronic databases for studies on PON1 activity in CRF patients with RRT such as hemodialysis (HD), peritoneal dialysis (PD), or renal transplantation (RTx), published before June 2023. A random-effects and network meta-analysis were performed. A total of 53 studies were eligibly identified. Compared to CRF patients without RRT, RTx patients had higher paraoxonase activity (standard mean difference (SMD), 1.76, 95% confidence interval (CI), 0.76–2.75), followed by HD (SMD, 0.73; 95% CI, 0.02–1.45) and PD patients. Likewise, RTx patients had higher arylesterase activity (SMD, 1.84, 95% CI, 0.18–3.50), followed by HD and PD patients. Also, paraoxonase activity was increased after HD (SMD, 0.59, 95% CI, 0.16–1.03). In conclusion, the overall data demonstrated that PON1 activity is higher in CRF patients with RRT, particularly RTx, followed by that of HD and PD. Measuring PON1 activity can also be included to the paraclinical toolbox for the management of RRT, in addition to the understanding of CRF-related pathophysiology. Regarding the selection of RRT types and their potential to prevent CVD, more research is required.

show abstract

Antibodies against Nε-homocysteinylated proteins in patients on different methods of renal replacement therapy

Abstract: Levels of antibodies against Nε-Hcy-proteins are similar in patients on long-term PD and HD. The level of tHcy is the only independent predictor of both antibodies irrespective of the dialysis method.

Cited by 3 publications

References 6 publications

Hyperhomocysteinemia in patients with chronic kidney disease and its relationship with the functional status of the cardiovascular system

Hyperhomocysteinemia in patients with chronic kidney disease and its relationship with the functional status of the cardiovascular system

Folic acid improves renal function — in what mechanism?

Paraoxonase 1 Activity and Renal Replacement Therapy for Chronic Renal Failure: A Meta-Analysis

Contact Info

Product

Resources

About